Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

5
Goldman to name David Solomon as CEO early this week - NYT

2h reuters
(Reuters) - Goldman Sachs Group Inc (GS.N) is expected to name David Solomon as its next chief executive officer early this week, the New York Times reported here on Sunday.
JBK GS.PRICL GSC TFG GS.PRB GS.PRA NYTAB GSJ GS.PRJ GS.PRI GS GLSSP GS.PRD GS.PRC GJS GS.PRN GS.PRK

5
PRESS DIGEST- British Business - July 16

4h reuters
The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
ROYMF JBK GS.PRICL GSC TFG GS.PRB GS.PRA RMG BYLOF BYG GSJ GS.PRJ GS.PRI GS GLSSP ROYMY GS.PRD GS.PRC GJS GS.PRN GS.PRK

42
Microsoft, Goldman Sachs, IBM and More Dow Stocks to Watch This Week

14h 247wallst
Earnings reporting season for the second quarter has gotten underway, and 24/7 Wall St. has put together a preview of the Dow Jones industrial average companies scheduled to report their quarterly results this week. Seven of the index’s 30 components are expected to share their results this week. The Dow has been subject to incredible volatility since January, but potentially this earnings season could stabilize the index.
GS.PRB GS.PRA AXP GS GLSSP IBM JBK GEC GE TRV GSC GS.PRICL TFG GSJ GS.PRJ GS.PRI JNJ GS.PRD GS.PRC TRI GNE MSFT GJS GS.PRN UNH GS.PRK

27
3M Repeats as Dow’s Most Woeful Stock

2018-07-14 247wallst
Industrial giant 3M Co. (NYSE: MMM) settled last week in as the worst-performing Dow Jones industrial stock of 2018 after nabbing the distinction the week before. Even though the stock added about 1.9% to its price last week, that wasn’t enough to make a difference. For the year to date, 3M stock is down 14.5%
MTSI PG CAT GS.PRB GS.PRA WMT GS GLSSP MMM JBK GEC GE CATR GSC GS.PRICL TFG GSJ GS.PRJ GS.PRI GS.PRD GS.PRC GNE GJS GS.PRN GS.PRK

11
Bankers Quit Goldman, Citigroup for Biotech Riches in Hong Kong - Bloomberg

2018-07-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
C.WSA DB GS.PRB GS.PRA GS C.WS.B GLSSP C.WS.A C.PRP JEF RWA C.PRU C.PRS JBK C C.PRL GSC GS.PRICL C.PRJ TFG C.PRK C.PRG GSJ C.PRC GS.PRJ GS.PRI C.PRPCL GS.PRD CGBBW LAZ GS.PRC GJS GS.PRN GS.PRK

10
Eyes Turn to Goldman, Morgan Stanley With Rivals Tapping M&A Windfall - Bloomberg

2018-07-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
C.WSA GS.PRB MS.PRE GS.PRA MS.PRF MS.PRG MS.PRA GS C.WS.B GLSSP C.WS.A C.PRP C.PRU MS C.PRS JBK C C.PRL GSC GS.PRICL C.PRJ TFG C.PRK C.PRG GSJ C.PRC GS.PRJ GS.PRI MS.PRI C.PRPCL GS.PRD MS.PRK CGBBW GS.PRC GJS GS.PRN GS.PRK

64
WGP / Western Gas Equity Partners, LP - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-13 fintel.io
This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
C.WSA GS.PRB GS.PRA WGP BAC GS C.WS.B GLSSP C.WS.A C.PRP C.PRU C.PRS JBK BAC C C.PRL GSC GS.PRICL C.PRJ TFG C.PRK CATB C.PRG GSJ C.PRC GS.PRJ GS.PRI C.PRPCL GS.PRD CGBBW GS.PRC GJS GS.PRN GS.PRK

5
SEC bribery lawsuit against Och-Ziff executives is dismissed

2018-07-13 channelnewsasia
A federal judge has dismissed the U.S. Securities and Exchange Commission's lawsuit accusing two former Och-Ziff Capital Management Group LLC executives of masterminding a scheme to funnel tens of millions of dollars of bribes to African officials.
JBK GS.PRICL GSC TFG GS.PRB GS.PRA GSJ GS.PRJ GS.PRI GS OZM GLSSP GS.PRD GS.PRC GJS GS.PRN GS.PRK

5
SEC bribery lawsuit against Och-Ziff executives is dismissed

2018-07-13 reuters
NEW YORK (Reuters) - A federal judge has dismissed the U.S. Securities and Exchange Commission’s lawsuit accusing two former Och-Ziff Capital Management Group LLC (OZM.N) executives of masterminding a scheme to funnel tens of millions of dollars of bribes to African officials.
JBK GS.PRICL GSC TFG GS.PRB GS.PRA GSJ GS.PRJ GS.PRI GS OZM GLSSP GS.PRD GS.PRC GJS GS.PRN GS.PRK

6
PNB aims for biggest bank profit after Nirav Modi fraud

2018-07-13 livemint
New Delhi: Punjab National Bank that saw its earnings wiped out by an unprecedented fraud aims to report the nation’s biggest bank profit by selling some assets, according to people familiar with the matter.
JBK GS.PRICL GSC BHUSANSTL TFG GS.PRB GS.PRA CG GSJ GS.PRJ GS.PRI GS GLSSP PNJZY 532461 GS.PRD GS.PRC PNB GJS GS.PRN 500055 GS.PRK

7
Will Muted Trading Business Impact Goldman (GS) Q2 Earnings?

2018-07-13 zacks
Muted trading business is unlikely to support Goldman Sachs’ (GS - Free Report) second-quarter 2018 earnings, to be reported on Jul 17. However, benefits of higher rates and relatively better performance of other segments — mainly investing and lending — are anticipated to aid earnings. Being an investment bank, Goldman is exposed to extreme market volatility. Volatility-driven growth in trading revenues, which supported the top line during the January-March quarter, is likely to have remained muted in the second quarter.
BBT JBK CMA GS.PRICL GSC TFG GS.PRB GS.PRA SAM GSJ GS.PRJ GS.PRI GS GLSSP GS.PRD GS.PRC GJS GS.PRN CFR GS.PRK

10
Coming Soon to an Ocean Near You: Ships Moving a Tiny Bit Slower - Bloomberg

2018-07-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
C.WSA GS.PRB GS.PRA GS C.WS.B GLSSP C.WS.A C.PRP EURN C.PRU C.PRS JBK EURN C C.PRL GSC GS.PRICL C.PRJ TFG C.PRK C.PRG GSJ C.PRC GS.PRJ GS.PRI C.PRPCL GS.PRD CGBBW GS.PRC GJS DHT GS.PRN GS.PRK

11
Funding for U.S. Fintech Startups Rose 40 Percent Last Quarter - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JBK SQ SQNXF GS.PRICL GSC TFG GS.PRB GS.PRA PYPL GSJ GS.PRJ GS.PRI GS GLSSP GS.PRD GS.PRC GJS GS.PRN GS.PRK

9
Wall Street Competes With Unregulated Banks for the Riskiest Loans - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
NMR MQBKY DB DGLD GS.PRB GS.PRA CS GS UGLD GLSSP 8604 NRSCF JEF MQG JBK DSLV VIIX GSC GS.PRICL CSSLF VIIZ TFG MCQEF GSJ GS.PRJ GS.PRI CSGKF N33 GS.PRD GS.PRC ZIV USLV GJS TVIX GS.PRN GS.PRK XIV

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...

CUSIP: 86311R301